BioCentury
ARTICLE | Clinical News

GLV-1h68: Phase I data

June 11, 2012 7:00 AM UTC

Data from 27 patients in an open-label, U.K. Phase I trial showed that escalating doses of IV GL-ONC1 were well tolerated and produced 9 cases of stable disease - 1 at 48 weeks, 3 at 24 weeks and 5 at...